Janus Henderson Group
CHRS icon

Janus Henderson Group’s Coherus Oncology CHRS Stock Holding History

Janus Henderson Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-26,496
Closed -$88.4K – 2536
2023
Q4 		$88.4K Buy
26,496
+18
+0.1% +$48 ﹤0.01% 2533
2023
Q3 		$99.2K Buy
26,478
+86
+0.3% +$397 ﹤0.01% 2520
2023
Q2 		$112K Sell
26,392
-27
-0.1% -$159 ﹤0.01% 2557
2023
Q1 		$181K Buy
26,419
+14,493
+122% +$112K ﹤0.01% 2518
2022
Q4 		$94.4K Sell
11,926
-11,926
-50% -$91.8K ﹤0.01% 2345
2022
Q3 		$228K Buy
23,852
+11,934
+100% +$121K ﹤0.01% 2343
2022
Q2 		$86K Buy
11,918
+1
+0% +$9 ﹤0.01% 2496
2022
Q1 		$154K Buy
11,917
+2
+0% +$25 ﹤0.01% 2496
2021
Q4 		$190K Buy
+11,915
New +$208K ﹤0.01% 2405
2021
Q3 		– Sell
-19,224
Closed -$266K – 2199
2021
Q2 		$266K Buy
19,224
+451
+2% +$6.39K ﹤0.01% 1544
2021
Q1 		$274K Sell
18,773
-487,276
-96% -$8.27M ﹤0.01% 1417
2020
Q4 		$8.79M Sell
506,049
-1,018,538
-67% -$18.1M ﹤0.01% 881
2020
Q3 		$28M Buy
1,524,587
+649,603
+74% +$12.1M 0.01% 639
2020
Q2 		$15.6M Buy
+874,984
New +$14.8M 0.01% 746

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Janus Henderson Group's CHRS Position: Q1 2024 in Review

Janus Henderson Group sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 26,496 shares — an estimated $88.4K sold.

Janus Henderson Group first reported a position in CHRS in Q2 2020 and held it in 14 quarters. The position peaked at $28M in Q3 2020. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Janus Henderson Group reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Janus Henderson Group sold 26,496 Coherus Oncology shares in Q1 2024, an estimated $88.4K.
  • Janus Henderson Group first reported a position in Coherus Oncology in Q2 2020 and held it in 14 quarters.
  • Janus Henderson Group's Coherus Oncology position peaked at $28M in Q3 2020.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Janus Henderson Group's 13F filing for Q1 2024, filed 15 May 2024.